SecBot SecBot

XOMA

XOMA Royalty Corp
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0000791908 Biotech & Drug Discovery
No price
Market cap
$503.8M
Small cap
Median target
$39.00
range $39.00–39.00
Short interest
914.9K
≈7.3% of shares · +1.8%
Days to cover
5.0
at average volume
Insider net
$0
no open-market trades · since Jul 14
New fund stakes
0
Q3 2026 13F · 6 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 1 report · latest
Balance 1 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jul 14. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 0 added (0 new), 6 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate $0.228 → $0.500 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +1.8% to 914.9K shares. 5.0 days to cover, ≈7.3% of shares.

Who's buying

13F· Q3 2026
0
new positions
6
exits
FundMoveSharesValue
MORGAN STANLEYEXIT0$0.00
BlackRock, Inc.EXIT0$0.00
GEODE CAPITAL MANAGEMENT, LLCEXIT0$0.00
FMR LLCEXIT0$0.00
VANGUARD CAPITAL MANAGEMENT LLCEXIT0$0.00
Woodline Partners LPADD1,114,363$47.4M
DIMENSIONAL FUND ADVISORS LPADD177,106$7.5M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED83,623$3.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Apr 2026
Recent actions
DateFirmActionRating
Apr 30, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Mar 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Feb 24, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Dec 11, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Dec 11, 2025Leerink Partners
MAINTAIN
MAINTAINOutperform
Dec 9, 2025LUCID CAPITAL MARKETS
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · since Jul 14
DateInsiderTypeValue
Jul 14, 2026
Montano Maricel Perea
Chief Legal Officer
Jul 14, 2026
OTHER65 sh
Jul 14, 2026
Montano Maricel Perea
Chief Legal Officer
Jul 14, 2026
TO ISSUER37,074 sh
Jul 14, 2026
Montano Maricel Perea
Chief Legal Officer
Jul 14, 2026
TO ISSUER11,316 sh
Jul 14, 2026
LIMBER JOSEPH M
Director
Jul 14, 2026
OTHER9,532 sh
Jul 14, 2026
LIMBER JOSEPH M
Director
Jul 14, 2026
TO ISSUER10,000 sh
Jul 14, 2026
LIMBER JOSEPH M
Director
Jul 14, 2026
TO ISSUER20,000 sh
Jul 14, 2026
LIMBER JOSEPH M
Director
Jul 14, 2026
TO ISSUER8,000 sh
Jul 14, 2026
LIMBER JOSEPH M
Director
Jul 14, 2026
TO ISSUER2,366 sh

Earnings setup

Estimates
$0.50
EPS estimate, this quarter
+120%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current FY$0.55$0.55–$0.55+266.7%$65.0M
Next FYNoneNoneNo data$0.00
Current Q$0.50$0.50–$0.50+185.7%$16.1M
Next Q$0.52$0.52–$0.52+100.0%$16.4M

Short side

FINRA· Jun 30, 2026
914,936
shares short
+1.8%
vs prior settlement
5.0
days to cover
≈7.3%
of shares outstanding
Trading halts
Jul 13, 2026DeletionResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Sep 30, 2026 Inst.
MORGAN STANLEY · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
BlackRock, Inc. · EXIT
0 shares ($0.00)
Aug 11, 2026 Earnings calendar
XOMA Q2 2026 Earnings Scheduled, 2026-08-11
Jul 27, 2026 SEC
XOMA Royalty Corp filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 27, 2026…
15-12G · Impact 7/10
Jul 14, 2026 SEC
XOMA Royalty Corp. completed its acquisition by Ligand Pharmaceuticals on July 14, 2026. Common stockholders received…
8-K · Impact 8/10
Jul 14, 2026 Insider
Montano Maricel Perea disposed of 65 shares
Chief Legal Officer
Jul 14, 2026 Insider
Montano Maricel Perea disposed of 37,074 shares
Chief Legal Officer
Jul 14, 2026 Insider
Montano Maricel Perea disposed of 11,316 shares
Chief Legal Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

5 filings · 3 press releases · 2 bullish · 1 bearish · 2 neutral
All XOMA filing & press-release reports (8)